| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4258060 | Transplantation Proceedings | 2012 | 4 Pages |
Abstract
ATG is safe and efficacious for use in kidney transplant recipients. Our results suggest that ATG should be considered for induction therapy in high-risk patients, such as those who have a kidney allograft from a deceased donor, high levels of panel reactive antibodies, and are undergoing retransplantation.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
J.M. Kim, H.R. Jang, C.H.D. Kwon, W.S. Huh, G.S. Kim, S.J. Kim, J.W. Joh, H.Y. Oh,